NEW YORK (TheStreet) -- Alkermes (ALKS) shares are up 7.41% to $$62.93 in morning trading on Tuesday after the pharmaceutical company announced that it will present the results of the data studies of the central nervous system drug candidates in schizophrenia and depression at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting in Miami.
The company will present on ALKS 3831, a possible schizophrenia treatment, as well as a presentation on ALKS 5461, a potential major depressive disorder treatment. The meeting runs from June 22 to June 25.
The presentation on ALKS 3831 will be one of the highlights of the event and the company will hold a conference call next Tuesday before the oral presentation to discuss the treatment.
TheStreet Ratings team rates ALKERMES PLC as a Sell with a ratings score of D+. TheStreet Ratings Team has this to say about their recommendation:
"We rate ALKERMES PLC (ALKS) a SELL. This is driven by several weaknesses, which we believe should have a greater impact than any strengths, and could make it more difficult for investors to achieve positive results compared to most of the stocks we cover. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income and disappointing return on equity."
Highlights from the analysis by TheStreet Ratings Team goes as follows:
- You can view the full analysis from the report here: ALKS Ratings Report